



UHID/MR No : SCHI.0000018699 Visit ID : SCHIOPV27177

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID

Collected : 09/Mar/2024 08:29AM
Received : 09/Mar/2024 09:12AM
Reported : 09/Mar/2024 11:48AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

: THTFYIUY

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240062314

Page 1 of 13







: Mr.RIZWAN ALAM

Age/Gender

: 35 Y 7 M 10 D/M

UHID/MR No

: SCHI.0000018699

Visit ID Ref Doctor : SCHIOPV27177

Emp/Auth/TPA ID

: Dr.SELF : THTFYIUY Collected

: 09/Mar/2024 08:29AM

Received

: 09/Mar/2024 09:12AM

Reported Status

: 09/Mar/2024 11:48AM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	15.7	g/dL	13-17	CYANIDE FREE COLOUROMETER
PCV	48.40	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	5.4	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	89.5	fL	83-101	Calculated
MCH	29.1	pg	27-32	Calculated
MCHC	32.5	g/dL	31.5-34.5	Calculated
R.D.W	13.9	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	7,340	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	Γ (DLC)			
NEUTROPHILS	45	%	40-80	Electrical Impedance
LYMPHOCYTES	43.1	%	20-40	Electrical Impedance
EOSINOPHILS	3.5	%	1-6	Electrical Impedance
MONOCYTES	7.4	%	2-10	Electrical Impedance
BASOPHILS	1	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	3303	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	3163.54	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	256.9	Cells/cu.mm	20-500	Calculated
MONOCYTES	543.16	Cells/cu.mm	200-1000	Calculated
BASOPHILS	73.4	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	1.04		0.78- 3.53	Calculated
PLATELET COUNT	155000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	04	mm at the end of 1 hour	0-15	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC, DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 13



Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:BED240062314





UHID/MR No : SCHI.0000018699

Visit ID : SCHIOPV27177

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : THTFYIUY Collected : 09/Mar/2024 08:29AM Received : 09/Mar/2024 09:12AM

Reported : 09/Mar/2024 11:48AM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

NO HEMOPARASITES SEEN

Page 3 of 13







Patient Name : Mr.RIZWAN ALAM
Age/Gender : 35 Y 7 M 10 D/M
UHID/MR No : SCHI.0000018699

Visit ID : SCHIOPV27177

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : THTFYIUY Collected : 09/Mar/2024 08:29AM
Received : 09/Mar/2024 09:12AM
Reported : 09/Mar/2024 11:48AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
BLOOD GROUP ABO AND RH FACTOR	R, WHOLE BLOOD EDTA			'
BLOOD GROUP TYPE	В			Forward & Reverse Grouping with Slide/Tube Aggluti
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination

Page 4 of 13









: Mr.RIZWAN ALAM

Age/Gender

: 35 Y 7 M 10 D/M

UHID/MR No

: SCHI.0000018699

Visit ID Ref Doctor : SCHIOPV27177 : Dr.SELF

Emp/Auth/TPA ID : THTFYIUY

Collected

: 09/Mar/2024 08:29AM

Received

: 09/Mar/2024 02:02PM

Reported

: 09/Mar/2024 02:54PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING , NAF PLASMA	267	mg/dL	70-100	GOD - POD

Kindly correlate clinically.

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	329	mg/dL	70-140	GOD - POD

Kindly correlate clinically.

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C (GLYCATED HEMOGLOBIN),	WHOLE BLOOD EDTA			

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:EDT240028225



Page 5 of 13





UHID/MR No : SCHI.0000018699

Visit ID : SCHIOPV27177

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : THTFYIUY Collected : 09/Mar/2024 08:29AM

Received : 09/Mar/2024 02:02PM Reported : 09/Mar/2024 02:54PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

HBA1C, GLYCATED HEMOGLOBIN	12.3	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	306	mg/dL	Calculated
COMMENTS			

Kindly correlate clinically.

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF >25%

- B: Homozygous Hemoglobinopathy.
- (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:EDT240028225

Page 6 of 13







UHID/MR No : SCHI.0000018699

Visit ID : SCHIOPV27177

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : THTFYIUY Collected : 09/Mar/2024 08:29AM Received : 09/Mar/2024 09:12AM

Reported : 09/Mar/2024 10:29AM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
LIPID PROFILE , SERUM							
TOTAL CHOLESTEROL	201	mg/dL	<200	CHE/CHO/POD			
TRIGLYCERIDES	193	mg/dL	<150	Enzymatic			
HDL CHOLESTEROL	44	mg/dL	>40	CHE/CHO/POD			
NON-HDL CHOLESTEROL	157	mg/dL	<130	Calculated			
LDL CHOLESTEROL	118.4	mg/dL	<100	Calculated			
VLDL CHOLESTEROL	38.6	mg/dL	<30	Calculated			
CHOL / HDL RATIO	4.57		0-4.97	Calculated			

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High	
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240		
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500	
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190	
HDL	≥ 60				
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220	

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- 4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 400 mg/dL. When Triglycerides are more than 400 mg/dL LDL cholesterol is a direct measurement.

Page 7 of 13



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology

SIN No:SE04654865





Patient Name : Mr.RIZWAN ALAM

Age/Gender : 35 Y 7 M 10 D/M UHID/MR No : SCHI.0000018699

Visit ID : SCHIOPV27177

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : THTFYIUY Collected : 09/Mar/2024 08:29AM Received : 09/Mar/2024 09:12AM

Reported : 09/Mar/2024 10:29AM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIVER FUNCTION TEST (LFT) , SERUM			1	
BILIRUBIN, TOTAL	1.70	mg/dL	0.20-1.20	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.40	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	1.30	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	73	U/L	<50	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	33.0	U/L	17-59	UV with P-5-P
ALKALINE PHOSPHATASE	142.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	7.40	g/dL	6.3-8.2	Biuret
ALBUMIN	4.30	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.10	g/dL	2.0-3.5	Calculated
A/G RATIO	1.39		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI .• Disproportionate increase in AST, ALT compared with ALP. Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.• ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment: Albumin- Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time) helps.

Page 8 of 13



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology

SIN No:SE04654865





: Mr.RIZWAN ALAM

Age/Gender

: 35 Y 7 M 10 D/M

UHID/MR No

: SCHI.0000018699

Visit ID

: SCHIOPV27177

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : THTFYIUY Collected

: 09/Mar/2024 08:29AM

Received

: 09/Mar/2024 02:12PM

Reported

Status

: 09/Mar/2024 05:20PM

Sponsor Name

: Final Report : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
RENAL PROFILE/KIDNEY FUNCTION	TEST (RFT/KFT) , SER	RUM	I	
CREATININE	0.68	mg/dL	0.66-1.25	Creatinine amidohydrolase
UREA	24.70	mg/dL	19-43	Urease
BLOOD UREA NITROGEN	11.5	mg/dL	8.0 - 23.0	Calculated
URIC ACID	3.87	mg/dL	3.5-8.5	Uricase
CALCIUM	9.40	mg/dL	8.4 - 10.2	Arsenazo-III
PHOSPHORUS, INORGANIC	3.25	mg/dL	2.5-4.5	PMA Phenol
SODIUM	134.1	mmol/L	135-145	Direct ISE
POTASSIUM	4.1	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	98.8	mmol/L	98 - 107	Direct ISE
PROTEIN, TOTAL	7.26	g/dL	6.3-8.2	Biuret
ALBUMIN	4.38	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	2.88	g/dL	2.0-3.5	Calculated
A/G RATIO	1.52		0.9-2.0	Calculated

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:BI18699713



Page 9 of 13





Patient Name : Mr.RIZWAN ALAM
Age/Gender : 35 Y 7 M 10 D/M
UHID/MR No : SCHI.0000018699

Visit ID : SCHIOPV27177

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : THTFYIUY Collected : 09/Mar/2024 08:29AM
Received : 09/Mar/2024 09:12AM
Reported : 09/Mar/2024 09:55AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	35.00	U/L	15-73	Glyclyclycine Nitoranalide

Page 10 of 13









UHID/MR No : SCHI.0000018699

Visit ID : SCHIOPV27177
Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : THTFYIUY

Collected : 09/Mar/2024 08:29AM Received : 09/Mar/2024 09:12AM

Reported : 09/Mar/2024 02:09PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
THYROID PROFILE TOTAL (T3, T4, TSF	l), SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	1.17	ng/mL	0.67-1.81	ELFA
THYROXINE (T4, TOTAL)	8.87	μg/dL	4.66-9.32	ELFA
THYROID STIMULATING HORMONE (TSH)	4.26	μIU/mL	0.25-5.0	ELFA

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 11 of 13



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:SPL24041257





: Mr.RIZWAN ALAM

Age/Gender

: 35 Y 7 M 10 D/M

UHID/MR No

: SCHI.0000018699

Visit ID Ref Doctor : SCHIOPV27177

Emp/Auth/TPA ID

: Dr.SELF : THTFYIUY Collected

: 09/Mar/2024 08:29AM

Received

: 09/Mar/2024 04:55PM

Reported Status

: 09/Mar/2024 07:14PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
COMPLETE URINE EXAMINATION (CUE) , URINE			<u>'</u>
PHYSICAL EXAMINATION				
COLOUR PALE YELLOW		PALE YELLOW	Visual	
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	5.0		5-7.5	Bromothymol Blue
SP. GRAVITY	1.030		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	POSITIVE (++)		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Dipstick
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE NEGATIVE NEGA		NEGATIVE	PYRROLE HYDROLYSIS	
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOPY	'		
PUS CELLS	2-3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-2	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 12 of 13









UHID/MR No : SCHI.0000018699

Visit ID : SCHIOPV27177

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : THTFYIUY Collected : 09/Mar/2024 08:29AM Received : 09/Mar/2024 04:55PM

Reported : 09/Mar/2024 07:13PM

Status : Final Report
Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
URINE GLUCOSE(FASTING)	NEGATIVE		NEGATIVE	Dipstick

*** End Of Report ***

Result/s to Follow:

 $GLUCOSE\left(POST\ PRANDIAL\right)-URINE$

Page 13 of 13





Name : Mr. RIZWAN ALAM

Age: 35 Y

Sex: M

Address : DELHI

Plan

: ARCOFEMI MEDIWHEEL MALE AHC CREDIT PAN

INDIA OP AGREEMENT

UHID:SCHI.0000018699

OP Number: SCHIOPV27177

Bill No: SCHI-OCR-9722

Date: 09.03.2024 08:28

Sno	Serive Type/ServiceName	Department
1	ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT	- PAN INDIA - FY2324
	I GAMMA GLUTAMYL TRANFERASE (GGT)	
2	2 LIVER FUNCTION TEST (LFT)	
3	3 GLUCOSE, FASTING	
2	4 HEMOGRAM + PERIPHERAL SMEAR	
4	5 DIET CONSULTATION	
(6 COMPLETE URINE EXAMINATION	
	7 URINE GLUCOSE(POST PRANDIAL)	
8	8 PERIPHERAL SMEAR	
Ġ	9 ECG	
10	0 RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT)	
1	I DENTAL CONSULTATION	
12	2 GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL)	
1.	3 URINE GLUCOSE(FASTING)	
14	4 HbA1c, GLYCATED HEMOGLOBIN	
15	5 X-RAY CHEST PA	
16	6 ENT CONSULTATION	
11	7 CARDIAC STRESS TEST(TMT)	
18	8 FITNESS BY GENERAL PHYSICIAN	
19	9 BLOOD GROUP ABO AND RH FACTOR	
20	0 LIPID PROFILE	
2	BODY MASS INDEX (BMI)	
22	22 OPTHAL BY GENERAL PHYSICIAN	
23	3 ULTRASOUND - WHOLE ABDOMEN	
24	4 THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)	



NAME:	RIZWAN ALAM	AGE/SEX:	35	YRS./M
UHID:	18699			
REF BY:	APOLLO SPECTRA	DATE:-	09.03.2	2024

ULTRASOUND WHOLE ABDOMEN

Liver: Appears normal in size, and shows increased parenchymal echogenicity which is most likely due to fatty changes. Intrahepatic biliary radicles are not dilated. CBD and portal vein are normal in calibre.

Gall Bladder: normally distended with clear lumen and normal wall thickness. No calculus or sludge is seen.

Pancreas and Spleen: Appears normal in size and echotexture.

Both Kidneys: are normal in size, shape, and echopattern. The parenchymal thickness is normal and cortico-medullary differentiation is well maintained. Pelvicalyceal systems are not dilated. No calculus or mass lesion is seen. Ureter is not dilated.

Urinary Bladder: is moderately distended and shows no obvious calculus or sediments. Bladder wall thickness is normal.

Prostate: normal in size, weight 18.5 Gms. It is normal in echotexture with no breech in the capsule.

No free fluid seen.

IMPRESSION: FATTY CHANGES IN LIVER GRADE III

Please correlate clinically and with lab. Investigations.

DR. MONICA CHHABRA Consultant Radiologist

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

ID: 18699 Rizwan Alam Male 35Years Req. No. :		09-03-2024 HR P PR QRS QT/QTcBz P/QRS/T RV5/SV1	09:48:23 - 75 bpm - 96 ms - 142 ms - 99 ms - 364/407 - 58/1/7 - 0.514/0.420	mv p	Diagnosis Information: Sinus Arrhythmia Abnormal Q Wave(III,aVF) Suspect Inferior Myocardial Low Voltage(Chest Leads) Report Confirmed by:	formation. ythmia ythmia Q Wave(II ferior Myo ge(Chest I ge(Chest by:	الملاح Cardial In Jeads	III,aVF) // // // // // // // // // // // // //			
	}	aVR	}	<u> </u>				<u>V4</u>			
	<u>}</u>	aW	<u> </u>	V_2		2	2	<u>Y5</u>		<u> </u>	
		aVF		V3				<u>V6</u>]		\	
	<u> </u>	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		<u>}</u>	}	<u>\{</u>	}	}	Ž Ž	\(\frac{\}{\}\)	
0.67~25Hz AC50 25mm/s 10mm/mV 4*2.5s+1r V2.22	25mm/s J	0mm/mV 4*2.	5s+1r V2.22	SEMIP	V1.92 APO)LLO SPE(CIALTY I	APOLLO SPECIALTY HOSPITALS			



DIGITAL X-RAY REPORT

NAME: RIZWAN	DATE: 09.03.2024
UHID NO: 18699	AGE: 35YRS/ SEX: M

X-RAY CHEST PA VIEW

Both the lung fields show no active parenchymal pathology.

Both the costophrenic angles are clear.

Heart size is normal.

Both the domes of diaphragm are normal.

Bony thorax appears normal.

IMPRESSION: NO SIGNIFICANT ABNORMALITY

Please correlate clinically and with lab investigations

DR. MONICA CHHABRA Consultant Radiologist

Dr. MONICA CHHABRA Consultant Radiologist DMC No. 18744 Apollo Spectra Hospitals New Delhi-110019

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com